Home › Steatotic Liver Disease › New York
Steatotic Liver Disease clinical trials in New York
17 studies for Steatotic Liver Disease are looking for participants at sites in New York.
Cities in New York
A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GSK Investigational Site, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07704892Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States
- New York Presbyterian/Weill Cornell, New York
- Columbia University Iriving School of Medicine, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT05832229A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
- Columbia University Irving Medical Center, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT05519475A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
- Research Foundation of SUNY - University of Buffalo, Buffalo
- NYU Langone Health, New York
- IMA Clinical Research Manhattan, New York
- and 2 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
- Akero Clinical Study Site, Buffalo
- Akero Clinical Study Site, Manhasset
- Akero Clinical Study Site, New York
- and 3 more
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH
- GSK Investigational Site, East Syracuse
- GSK Investigational Site, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Albany
- 89bio Clinical Study Site, New York
- 89bio Clinical Study Site, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Sep 3, 2026 · NCT06419374A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Albany
- 89bio Clinical Study Site, Carmel
- 89bio Clinical Study Site, New York
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 3, 2026 · NCT06318169Human Models of Selective Insulin Resistance: Alpelisib, Part I
- Columbia University Irving Medical Center, New York
RecruitingPhase 1Healthy volunteers welcome
Ages 18 to 70 · All sexes · Updated Aug 24, 2026 · NCT06354088A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
- GSK Investigational Site, New York
RecruitingPhase 2
Ages 18 to 70 · All sexes · Updated Aug 3, 2026 · NCT06613698A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH
- GSK Investigational Site, East Syracuse
- GSK Investigational Site, New York
- GSK Investigational Site, New York
RecruitingPhase 3
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH
- GSK Investigational Site, New York
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043Effect of Insulin Lowering on Lipogenesis
- Columbia University Irving Medical Center, New York
RecruitingPhase 1
Ages 18 to 65 · All sexes · Updated Jul 6, 2026 · NCT07403604Non-Invasive Quantification of Liver Health in NASH (N-QUAN)
- Icahn School of Medicine at Mount Sinai, New York
Recruiting
Ages 18 to 75 · All sexes · Updated May 19, 2026 · NCT04054310Diet and Meal Timing in Patients With Metabolic Dysfunction Associated Steatoic Liver Disease
- Weill Cornell Medicine, New York
RecruitingHealthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Feb 27, 2026 · NCT05332613High Fructose Diet, the Gut Microbiome, and Metabolic Health
- Mount Sinai Morningside, New York
RecruitingHealthy volunteers welcome
Ages 25 to 45 · All sexes · Updated Dec 17, 2025 · NCT06329544Blood Collection Biorepository for Liver Disease Research
- University at Buffalo, Buffalo General Medical Center, Buffalo
RecruitingObservational studyHealthy volunteers welcome
Ages 7 and older · All sexes · Updated Aug 27, 2025 · NCT03025074From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.